ライフサイエンスコーパス: intranasal administration

1 ronchoconstriction in vivo model in mice via intranasal administration.

2 e and cause disease in BALB/c mice following intranasal administration.

3 uroprotection by PcTX was also achievable by intranasal administration.

4 acquired at 22-28 and at 30-36 minutes post-intranasal administration.

5 responses to the Env and Gag proteins after intranasal administration.

6 a 1-microg dose of EtxB was protective after intranasal administration.

7 e GTF peptide vaccines HDS and HDS-GLU after intranasal administration.

8 eafferentation of OB within 3 days following intranasal administration.

9 from lethal influenza virus challenge after intranasal administration.

10 Typhi vaccine strain CVD 908-htrA following intranasal administration.

11 ted delivery of immunogens to NALT following intranasal administration.

12 detected in the CNS within minutes following intranasal administration.

13 ded nanostructured lipid carriers (NLCs) for intranasal administration.

14 )-based polymeric nanoparticles (NP-EDV) for intranasal administration.

15 fficiency and enhanced cellular uptake after intranasal administration.

16 utralizing antibodies to hemagglutinin after intranasal administration.

17 reaches the brain following intravenous and intranasal administration.

18 onotide to the cerebrospinal fluid (CSF) via intranasal administration.

19 mes was detected in PD mouse brain following intranasal administration.

20 um concentration (Tmax) in CSF was less upon intranasal administration (15min) compared to i.v. admin

21 Detectable in serum within 2 minutes of intranasal administration, 30 mg seletracetam delayed se

22 this question by contrasting two methods of intranasal administration (a standard nasal spray, and a

23 d avoid potential contraindications based on intranasal administration alone and provide opportunitie

24 portantly, this mode of protection following intranasal administration also applied to non-neutralize

25 eficient mice were infected with H1N1 PR8 by intranasal administration and course of influenza pneumo

26 ested in influenza-infected mice by oral and intranasal administration and found to be very effective

27 mits VSV replication in the mouse lung after intranasal administration and reduces virus spread to ot

28 etrated pulmonary epithelial cells following intranasal administration, and nocardiae were recovered

29 Live-attenuated pediatric vaccines for intranasal administration are being developed for human

30 h the CNS and the cellular CNS targets after intranasal administration are not fully understood.

31 tokine responses to allergens, while in vivo intranasal administration at very low doses led to local

32 Intranasal administration avoids first-pass metabolism a

33 At 6 h, and up to 48 h after intranasal administration, beads were observed as intrac

34 These results suggest that intranasal administration bypasses the blood-brain barri

35 ed transgene expression by over 3-fold after intranasal administration compared to intravenous admini

36 trans-crosslinking, decavalent avidity, and intranasal administration contribute to the broader prot

37 These results suggest that intranasal administration could be a potential noninvasi

38 monitor drug delivered to the brain, and the intranasal administration could increase effective dose

39 Intranasal administration efficiently delivered mAb2A7 i

40 ld increase in skin SNA during the period of intranasal administration followed by a sustained 2.4-fo

41 cles (VLPs) displaying RBD of SARS-CoV-2 for intranasal administration in a murine model.

42 or, accumulates in cerebrospinal fluid after intranasal administration in macaques and humans and mod

43 ibroblasts from pediatric patients and after intranasal administration in mice.

44 On intranasal administration in the rat at a resveratrol do

45 Mucosal (intranasal) administration in mice of the purified chime

46 iposome-based drug delivery to the brain via intranasal administration, in which the liposome could p

47 Likewise, nCB intranasal administration induced emphysema in mouse lun

48 ritoneal, or intranasal immunization routes, intranasal administration induced the strongest protecti

49 fective adenoviruses encoding human ACE2 via intranasal administration into BALB/c mice and establish

50 Intranasal administration is becoming increasingly more

51 While eTIP1 replication following intranasal administration is limited to the nasal cavity

52 Intranasal administration led to rapid lung alveolar mac

53 mice had a similar course of infection after intranasal administration of 16M, validating the usefuln

54 in Stat6-/- mice were targeted via the daily intranasal administration of 200 ng of IL-13-PE38QQR (IL

55 Intranasal administration of 2155-17 protected WT mice a

56 emotion classification task 45 minutes after intranasal administration of 26 IU of oxytocin or placeb

57 Intranasal administration of 3 x 10(11) vg donor templat

58 Intranasal administration of 6 potently inhibits feeding

59 The intranasal administration of 7DW8-5 prior to virus expos

60 morbidly obese patients and the finding that intranasal administration of a fragment of melanocortin

61 Intranasal administration of a Gag-Fc/CpG vaccine protec

62 d BALB/c mice compared to controls following intranasal administration of a lethal dose of B. dermati

63 munization regimens that involved an initial intranasal administration of a live influenza virus vect

64 Here, we compare intramuscular and intranasal administration of a live, replication-deficie

65 in airway epithelial cells and myocytes, and intranasal administration of a PAR2 agonist stimulated m

66 Intranasal administration of a single antagomiR-122-5p d

67 Intranasal administration of a single dose of MMI-Ps1 im

68 In both mice and ferrets, intranasal administration of a single dose of the eq/GA/

69 ed by the internal gene segments from AA ca. Intranasal administration of a single dose of the three

70 In conclusion, we show that intranasal administration of AAV vectors results in effi

71 We demonstrated that intranasal administration of adeno-UGRP1 successfully de

72 Intranasal administration of adenovirus expressing IL-17

73 Overall, our data show that intranasal administration of Ag with NE induces TLR2 and

74 Therefore, this study compared intranasal administration of AgNPs versus soluble silver

75 Intranasal administration of AGPs induced intrapulmonary

76 Intranasal administration of allergen induced rises of a

77 Intranasal administration of Alternaria challenge reduce

78 Similarly, intranasal administration of an AAV2/5-CC10-factor IX ve

79 lthy participants and studied the effects of intranasal administration of an arginine vasopressin 1A

80 Intranasal administration of an El Tor O1 V. cholerae st

81 Our results show that intranasal administration of an engineered IgM can impro

82 A single intranasal administration of an eukaryotic expression ve

83 nduced in DBA/1 mice and monitored following intranasal administration of an IL-10 plasmid (pG-IL-10)

84 The intranasal administration of an IL-13 immunotoxin chimer

85 nst an airborne challenge with P. carinii by intranasal administration of antibody.

86 Intranasal administration of antigen into c-Kit-mutant m

87 ations, the effect of either subcutaneous or intranasal administration of B-(9-23) on the incidence o

88 ted here indicate that both subcutaneous and intranasal administration of B-(9-23) resulted in a mark

89 th infection in normal C57BL/6 animals after intranasal administration of B. melitensis 16M.

90 This study tested the hypothesis that intranasal administration of BCG with cholera toxin (CT)

91 In addition, intranasal administration of beta-toxin evoked the chara

92 A single intranasal administration of BHPIV3 expressing the SARS-

93 n the responses in humans receiving a single intranasal administration of BPZE1.METHODSWe performed m

94 In addition, by using intranasal administration of BrdU during infection, we o

95 Intranasal administration of C3aR agonists within a conv

96 In vivo intranasal administration of CC1-PPRH in K18-hACE2 mice

97 Intranasal administration of CCL2, IFN-gamma, or CXCL9 w

98 ncreased lung and spleen loads of organisms, intranasal administration of CD44TA-LIP led to a ten-fol

99 Local, intrapulmonary blockade of CD49d by intranasal administration of CD49d mAb inhibited all sig

100 Intranasal administration of CDG did not induce TNF-alph

101 Intranasal administration of ChAd-SARS-CoV-2-S is a cand

102 y intramuscular mRNA vaccination followed by intranasal administration of ChAdOx1 nCoV-19 vaccine in

103 Importantly, intranasal administration of cholecystokinin A receptor

104 Intranasal administration of CLH001 to BALB/c and NOD SC

105 pletion of recovered alveolar macrophages by intranasal administration of clodronate-containing lipos

106 These findings suggest that intranasal administration of CM(QE) holds promise as a s

107 We recently demonstrated that intranasal administration of COVID-19 convalescent plasm

108 In a pilot experimental colds study, intranasal administration of CP buffer, compared with no

109 The data establish that intranasal administration of CpG ODN 1 day prior to leth

110 Further, intranasal administration of CR9114 fully protects mice

111 Stimulation of transplanted cells with daily intranasal administration of CTZ enhanced axonal myelina

112 Our data demonstrate that intranasal administration of CuMV(TT) -RBD induces a pro

113 Intranasal administration of current vaccines has proven

114 in A (IgA) responses were not detected after intranasal administration of diepitopic HDS-GLU peptide

115 Rats were exposed to intranasal administration of E-selectin every other day

116 We report that intranasal administration of either fibroblast growth fa

117 Intranasal administration of either IL-4 or IL-13 confer

118 h the expression and identity task after the intranasal administration of either OT or saline in a wi

119 Intranasal administration of ELP-EEP13 combined with Cre

120 Here we explored the effects of intranasal administration of exogenous recombinant human

121 More important, replenishment of Sema3E by intranasal administration of exogenous Sema3E protects m

122 way in intact mouse brains was studied using intranasal administration of fluorescently labeled album

123 We observed that a single intranasal administration of GAD65 peptides to 2-3-wk-ol

124 Our data indicate that intranasal administration of gangliosides could reduce n

125 broad variety of cell types in vitro and use intranasal administration of HB-EGF in acute and post-ac

126 mmation was subsequently induced by means of intranasal administration of house dust mite (HDM) extra

127 10Ralpha) knockout mice by means of repeated intranasal administration of house dust mite (HDM).

128 rway disease was induced in mice by repeated intranasal administration of house dust mite or the fung

129 Intranasal administration of IFN-gamma to mice after IL-

130 Intranasal administration of IL-12 to mice nasally immun

131 sive cells in the lung were targeted via the intranasal administration of IL-13-PE38QQR (IL-13-PE), c

132 Intranasal administration of IL-17 revealed a crucial ro

133 Moreover, intranasal administration of Il-1beta promoted clearance

134 Intranasal administration of IL-25 into naive mice induc

135 Intranasal administration of IL-25 or IL-33 induced IL-1

136 In contrast, intranasal administration of IL-25-expressing adenovirus

137 RB KO and IL-17RA KO mice did not respond to intranasal administration of IL-25.

138 Intranasal administration of IL-33 to wild-type mice ind

139 In wild-type mice, intranasal administration of IL-37 ablated allergic airw

140 Similarly, intranasal administration of IL-4 enhanced bacterial cle

141 n, with loss of smell in mice evoked only by intranasal administration of IL-4, but not IL-13.

142 Intranasal administration of IL-5 caused eosinophil migr

143 Intranasal administration of IL-5 caused eosinophil migr

144 Furthermore, intranasal administration of IL-5 restored the impairmen

145 rotection in the lung could be stimulated by intranasal administration of inactivated LVS together wi

146 n be protected against rotavirus shedding by intranasal administration of individual rotavirus protei

147 8 T cells using anti-CD8 Ab treatment before intranasal administration of infectious RSV.

148 All volunteers underwent intranasal administration of influenza A/Wisconsin/67/20

149 A single intranasal administration of influenza hemagglutinin or

150 Here, we treated mice with daily intranasal administration of insulin (1.75 U/day) for on

151 ese findings show a therapeutic potential of intranasal administration of insulin before surgery to r

152 subtype and was fully blocked through daily intranasal administration of interferon to either inocul

153 using mouse embryonic lung organ culture and intranasal administration of interleukin (IL) 10 reveale

154 Finally, intranasal administration of just 100 PFU of the WA1-Del

155 The effect of intranasal administration of keratinocyte growth factor

156 CE2 mice infected with wild-type SARS-CoV-2, intranasal administration of LCB1-Bn significantly impro

157 In mice, intranasal administration of leptin produced elevated br

158 hamsters, both prophylactic and therapeutic intranasal administration of lipid-nanoparticle TIPs dur

159 l and physiochemical properties suitable for intranasal administration of lipophilic drugs.

160 Mice received unilateral intranasal administration of lipopolysaccharide (LPS) or

161 to promote this infection, we depleted AM by intranasal administration of liposome-encapsulated clodr

162 A single intranasal administration of live attenuated vaccine wit

163 Intranasal administration of low dosage (<1.2 mumol/kg/d

164 lic airway inflammation was induced by daily intranasal administration of LPS plus house dust mite (L

165 a model of acute lung injury established by intranasal administration of LPS to mice.

166 Intranasal administration of LTC4 to OVA-sensitized C57B

167 Finally, intranasal administration of MacLNP-encapsulated TAK1 si

168 To investigate the effect of intranasal administration of major birch pollen allergen

169 reduce the level of protection stimulated by intranasal administration of MBP::VP6.

170 We previously showed that intranasal administration of microbial products from far

171 Similarly, intranasal administration of MOG(35-55) before EAE induc

172 Furthermore, intranasal administration of mouse genomic DNA with Alte

173 Intranasal administration of MSCs was well tolerated in

174 el of temporal lobe epilepsy to determine if intranasal administration of nanoparticles containing TR

175 In mice, intramuscular or intranasal administration of nanoparticles with the lead

176 Intranasal administration of neutralizing anti-IL-12 at

177 Therefore, intranasal administration of NLCs of ATS has great poten

178 The results show that intranasal administration of non-pregnant sheep with a l

179 ses of allergen-specific IgE levels, whereas intranasal administration of omalizumab did not enhance

180 xamined pairs of friends while dancing after intranasal administration of OT or placebo.

181 cognition and behavior, we examined whether intranasal administration of OT would modulate synchroni

182 We have shown that prophylactic intranasal administration of our lead fusion inhibitor e

183 Intranasal administration of OVA induced an initial phas

184 inconsistencies observed following systemic intranasal administration of OXT and provide important i

185 ovide the first behavioral evidence that the intranasal administration of OXT stimulates men in a mon

186 Following intranasal administration of oxytocin (OT), we measured,

187 Intranasal administration of oxytocin (vs placebo) incre

188 ale subjects, we investigated the effects of intranasal administration of oxytocin and vasopressin, w

189 Thus, intranasal administration of oxytocin reduced stress eff

190 s who completed the trial showed that 6-week intranasal administration of oxytocin significantly redu

191 Importantly, intranasal administration of P4 at an early stage of inf

192 Intranasal administration of papain stimulated ILC2s and

193 la response to fearful faces following acute intranasal administration of PBO or OXT.

194 While intranasal administration of plasmid DNA nanoparticles (

195 These results show that intranasal administration of PspA together with mCT S61F

196 ylated AM G proteins both in vitro and after intranasal administration of PT in mice and that the dur

197 Additionally, we showed that intranasal administration of PT inhibits lipopolysacchar

198 tly outcompeted by the wild-type strain, and intranasal administration of purified ACT did not increa

199 ensitized fB-/- mice could be restored after intranasal administration of purified factor B before th

200 Intranasal administration of purified PT up to 14 days p

201 Biodistribution studies following intranasal administration of radiolabeled peptide demons

202 mococcal disease in TLR4-defective mice, the intranasal administration of rBPI21 following intranasal

203 ent and bacterial clearance were restored by intranasal administration of recombinant CXCL5.

204 Furthermore, intranasal administration of recombinant HRF elicited ro

205 Bolstering the antiviral response with intranasal administration of recombinant IFN-I reduced v

206 Intranasal administration of recombinant IL-10 accelerat

207 Furthermore, intranasal administration of recombinant mindin signific

208 In tPA knockout mice, intranasal administration of recombinant tPA protein 6 h

209 Mice were infected via intranasal administration of respiratory syncytial virus

210 Importantly, intranasal administration of rIFN-gamma largely rescued

211 A single intranasal administration of rJPV- SH-H5 protected mice

212 Intranasal administration of rNDV-based vaccine candidat

213 A prime-boost intranasal administration of RSVNanoVax in BALB/c mice s

214 with vancomycin or streptomycin by repeated intranasal administration of Saccharopolyspora rectivirg

215 Systemic or intranasal administration of salmeterol protected agains

216 n hamsters-following single-dose, atraumatic intranasal administration of SARS-CoV-2/Victoria-01.

217 Treatment with the SOD mimetic MnTBAP and intranasal administration of SOD-containing polyketal mi

218 did not generate an anti-B5 immune response, intranasal administration of soluble pB5 led to a rise o

219 Repetitive intranasal administration of soluble peptide induces per

220 Intranasal administration of SPEA induced airway inflamm

221 Human imaging studies have revealed that intranasal administration of the "prosocial" hormone oxy

222 Intranasal administration of the adenosine receptor anta

223 Intranasal administration of the combined LOS conjugates

224 against MPXV disease was demonstrated by the intranasal administration of the mouse cytokine to CAST/

225 Intranasal administration of the mucus penetrating DNA n

226 Because the intranasal administration of the neuropeptide oxytocin h

227 Thus, a single intranasal administration of the poxvirus modified vacci

228 Here, we investigated if intranasal administration of the PRS regimen V antibioti

229 Chronic intranasal administration of the S-palmitoylation inhibi

230 A single intranasal administration of the Salmonella clones to mi

231 We studied the effects of intranasal administration of the SCFAs acetate, butyrate

232 The current study evaluated whether intranasal administration of the sialic acid analog 4-gu

233 In contrast, repeated intranasal administration of the specific peptide result

234 Intranasal administration of these bacteria or transplan

235 Intranasal administration of these peptides results in p

236 Strikingly, intraperitoneal or intranasal administration of this genome, which we terme

237 Daily intranasal administration of this LNA ASO in the COVID-1

238 ceived focus in numerous studies associating intranasal administration of this peptide with various a

239 In initial studies, we showed that intranasal administration of this plasmid (along with Do

240 After a single intranasal administration of this vector, secretion of E

241 Ag alone, we treated OVA-immunized mice with intranasal administration of trinitrophenyl-OVA or trini

242 Here we show that intranasal administration of virus-like particles (VLPs)

243 Whereas, intranasal administration of ziconotide in the form of i

244 e arm at 0, 1, and 4 months, followed by two intranasal administrations of 30 mug unadjuvanted vaccin

245 lacebo-controlled crossover trial of 6 weeks intranasal administrations of oxytocin (48 IU/day) and p

246 placebo-controlled 6-week trials of repeated intranasal administrations of oxytocin (48 IU/day) in ad

247 formation in gene therapy by prior mucosal (intranasal) administration of a peptide representing a h

248 ment 1 (244 DI virus) and shown earlier that intranasal administration protects mice from lethal dise

249 Intranasal administration provides a non-invasive drug d

250 cy of the unmodified micelle formulation via intranasal administration remains limited.

251 Moreover, intranasal administration resulted in an increase in pot

252 Combining FUS with intranasal administration resulted in enhanced delivery

253 Intranasal administration resulted in tenfold higher CSF

254 gainst a potential future pandemic using the intranasal administration route.

255 In addition, intranasal administration showed the capacity to induce

256 Following intranasal administration, the model paramyxovirus simia

257 Following intranasal administration, the severe acute respiratory

258 Following intranasal administration, the virus replicated in the l

259 After intranasal administration, these specific CEST contrasts

260 Daily intranasal administration to ferrets completely prevente

261 ntral nervous system (CNS) therapy following intranasal administration to mice using a battery of ana

262 y, intravitreal administration to the eye or intranasal administration to the lung resulted in a pote

263 AuNR in glioblastoma (GBM) tumors following intranasal administration was also proven which opens do

264 bacter jejuni infection of mice initiated by intranasal administration was investigated as a potentia

265 brains was observed within 10 min following intranasal administration which gradually reduced over t

266 g-specific siRNA delivery can be achieved by intranasal administration without the need for viral vec